Kinetic properties of human thymidylate synthase, an anticancer drug target

Biochemical and Biophysical Research Communications

Volumn 307, Issue 2, 2003, Pages 297-300

  Sergeeva, Oksana A ^a   Khambatta, H Godrej ^a   Cathers, Brian E ^a   Sergeeva, Maria V ^a  

^a NewBiotics Inc   (United States)

Author keywords

Bromovinyldeoxyuridine; Cancer; Thymidylate synthase

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE MONOPHOSPHATE; ANTINEOPLASTIC AGENT; FOLIC ACID DERIVATIVE; NB 1011; RECOMBINANT ENZYME; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ARTICLE; DRUG SELECTIVITY; DRUG TARGETING; KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

EID: 0038690385     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)01173-2     Document Type: Article

References (10)

1. Salonga D., Danenberg K.D., Johnson M., Metzger R., Groshen S., Tsao-Wei D.D., Lenz H.J., Leichman C.G., Leichman L., Diasio R.B., Danenberg P.V. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 2000;1322-1327.
2. Iqbal S., Lenz H.J. Determinants of prognosis and response to therapy in colorectal cancer. Curr. Oncol. Rep. 2001;102-108.
3. ′ -deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer Eur. J. Cancer. 34:1998;296-306.
4. Copur S., Aiba K., Drake J.C., Allegra C.J., Chu E. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem. Pharmacol. 49:1995;1419-1426.
5. Lackey D.B., Groziak M.P., Sergeeva M., Beryt M., Boyer C., Stroud R.M., Sayre P., Park J.W., Johnston P., Slamon D., Shepard H.M., Pegram M. Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase. Biochem. Pharmacol. 61:2001;179-189.
6. Li Q., Boyer C., Lee J.Y., Shepard H.M. A novel approach to thymidylate synthase as a target for cancer chemotherapy. Mol. Pharmacol. 59:2001;446-452.
7. Neuteboom S.T., Karjian P.L., Boyer C.R., Beryt M., Pegram M., Wahl G.M., Shepard H.M. Inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, bax, and GADD45 induction. Mol. Cancer Ther. 1:2002;377-384.
8. ′ -deoxyuridine, results in modification of cellular proteins not DNA Biochem. Pharmacol. 65:2003;823-831.
9. ′ -deoxyuridylate J. Biol. Chem. 258:1983;13627-13631.
10. Mini E., Biondi C., Morganti M., Napoli C., Mazzoni P., Cianchi F., Tonelli F., Cortesini C., Capaccioli S., Ficari F., Quattrone A., Rossi S., Mazzei T. Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors. Oncol. Res. 11:1999;437-445.